Venture capital investment in New England dropped 45 percent in the most recent quarter, largely due to fewer deals in biotechnology and medical devices. The national trend is down, too, though not as much, according to a new report from the National Venture Capital Association and PricewaterhouseCoopers.
It’s definitely a challenge for the Boston area, where biotech startups in particular have been a good source of new, high-skill jobs and the infrastructure spending that accompanies business formation and growth. Quarterly figures bounce around, and the overall year still looks ok. But the trend is clearly something to worry about here.
To read the full, original article click on this link: How much will slumping VC investment hurt the life sciences?
